Stomach cancer

Gastric cancer
#Antibody #FDA #Gastrointestinal #Oncology #Phase III trial #Stomach cancer #Transcenta

Antibody for gastric cancer progresses to Phase III trials

The US Food and Drug Administration (FDA) has granted clearance to Transcenta to proceed with its TranStar 301 global Phase III pivotal trial of Osemitamab (TST001) for gastric cancer. The trial will investigate the drug in combination with Nivolumab and chemotherapy as a first-line treatment in patients with HER2-negative, CLDN18.2… Read More

#Cancer Research #News #Regulatory

Stomach cancer cells
#ATR inhibitors #Cancer #Cancer research #Cancer Research UK #CRISPR #Drug resistance #Gene editing #Genetic study #Stomach cancer #The Institute of Cancer Research

Study reveals how stomach cancers develop drug resistance

Scientists have shown how stomach cancers can develop resistance to a new class of drugs called ATR inhibitors by switching off the activity of two key genes – raising the possibility of outsmarting cancer by predicting drug resistance in advance.  The findings could pave the way for… Read More

#Cancer Research #News